TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06489613

Intervention type: DIAGNOSTIC_TEST
Intervention: M protein detection by iMS-LC Assay
Description: iMS-LC Assay (intact M-protein Screening-Light Chain Assay) technology is a new method for the specific identification of M-proteins in peripheral blood, based on mass spectrometry recognition of intact clonal immunoglobulin light chains. Combined with AI algorithm models, M-proteins can be easily distinguished from the polyclonal background, enabling automated identification and quantitative analysis of M-proteins.~Previous studies have shown that the detection limit of the iMS-LC Assay is several times higher than that of IFE. Additionally, the iMS-LC Assay requires only 5 μL of peripheral blood serum for detection, offering advantages over traditional methods in terms of higher sensitivity, non-invasiveness, lower sample volume requirements, reduced detection costs, and higher throughput.

Intervention type: DIAGNOSTIC_TEST
Intervention: M protein detection by iMS-LC Assay
Description: iMS-LC Assay (intact M-protein Screening-Light Chain Assay) technology is a new method for the specific identification of M-proteins in peripheral blood, based on mass spectrometry recognition of intact clonal immunoglobulin light chains. Combined with AI algorithm models, M-proteins can be easily distinguished from the polyclonal background, enabling automated identification and quantitative analysis of M-proteins.~Previous studies have shown that the detection limit of the iMS-LC Assay is several times higher than that of IFE. Additionally, the iMS-LC Assay requires only 5 μL of peripheral blood serum for detection, offering advantages over traditional methods in terms of higher sensitivity, non-invasiveness, lower sample volume requirements, reduced detection costs, and higher throughput.
Study: NCT05978765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Cupping
Description: treated by using dynamic cupping. Heating pad will be applied for 10 minutes as a base treatment then olive oil or petroleum jelly will be applied and a cup will be placed, a vacuum will be created by using vacuum pump then the cup will be moved to and fro or in figure of 8 for 5 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Cupping
Description: treated by using dynamic cupping. Heating pad will be applied for 10 minutes as a base treatment then olive oil or petroleum jelly will be applied and a cup will be placed, a vacuum will be created by using vacuum pump then the cup will be moved to and fro or in figure of 8 for 5 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Cupping
Description: treated by using dynamic cupping. Heating pad will be applied for 10 minutes as a base treatment then olive oil or petroleum jelly will be applied and a cup will be placed, a vacuum will be created by using vacuum pump then the cup will be moved to and fro or in figure of 8 for 5 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Cupping
Description: treated by using dynamic cupping. Heating pad will be applied for 10 minutes as a base treatment then olive oil or petroleum jelly will be applied and a cup will be placed, a vacuum will be created by using vacuum pump then the cup will be moved to and fro or in figure of 8 for 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: e treated by soft tissue myofascial release. Heating pad will be applied for 10 minutes as a base treatment,petroleum jelly will be applied to the area follow by soft tissue myofascial release technique for 5 minutes either criss cross, along the fiber or in figure of 8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: e treated by soft tissue myofascial release. Heating pad will be applied for 10 minutes as a base treatment,petroleum jelly will be applied to the area follow by soft tissue myofascial release technique for 5 minutes either criss cross, along the fiber or in figure of 8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: e treated by soft tissue myofascial release. Heating pad will be applied for 10 minutes as a base treatment,petroleum jelly will be applied to the area follow by soft tissue myofascial release technique for 5 minutes either criss cross, along the fiber or in figure of 8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: e treated by soft tissue myofascial release. Heating pad will be applied for 10 minutes as a base treatment,petroleum jelly will be applied to the area follow by soft tissue myofascial release technique for 5 minutes either criss cross, along the fiber or in figure of 8
Study: NCT04894253

Intervention type: BIOLOGICAL
Intervention: SRAS-CoV-2 vaccination immunological response
Description: Follow for 18 months a single group of 30 patients with systemic lupus after their SRAS-CoV-2 vaccination.~Intervention includes immunological analysis on additional volume of blood collected as part of routine care.
Study: NCT05518929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: The sedation of gastrointestinal endoscopy with Ciprofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The sedation of gastrointestinal endoscopy with Propofol
Study: NCT06486753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chevron osteotomy bunion surgery with lateral soft tissue release
Description: Lateral soft tissue release is often performed in hallux valgus correction, and there is preliminary evidence to suggest it may be useful in improving post-surgical outcomes for the Chevron osteotomy bunion surgery.
Study: NCT05934734

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational cross-sectional study. No intervention will be provided. Participants will be assessed and stratified into four cohorts based on self-reported symptom severity of thoracic outlet syndrome using a visual analog scale (VAS) to investigate the relationship between symptom severity and upper extremity function/neural integrity.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational cross-sectional study. No intervention will be provided. Participants will be assessed and stratified into four cohorts based on self-reported symptom severity of thoracic outlet syndrome using a visual analog scale (VAS) to investigate the relationship between symptom severity and upper extremity function/neural integrity.
Study: NCT06032702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tooth alignment
Description: Alignment will be assessed by Little's Irregularity Index

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tooth alignment
Description: Alignment will be assessed by Little's Irregularity Index
Study: NCT04782596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterium nasal septum resection
Description: Posterium nasal septum resection is required to ensure approach during transnasal endoscopic pituitary surgery in patients with pituitary adenoma.
Study: NCT05487872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness skills training to reduce experiential avoidance and anxiety symptoms
Description: The intervention aimed to increase participants' mindfulness skills which may be critical in decreasing general experiential avoidance and anxiety symptoms
Study: NCT05588830

Intervention type: DRUG
Intervention: Belimumab
Description: Belimumab, 10mg/kg, was administered intravenously on the 0, 14 and 28 days, and then once every 28 days until the 24th week

Intervention type: DRUG
Intervention: Telitacicept
Description: Telitacicept is injected subcutaneously, 160mg/time, once a week, for a total of 24 weeks
Study: NCT06017765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Training
Description: The Meditation Training consists of 8 weekly sessions of Mindfulness Training and is adapted from the group-based Stress Management and Resiliency Training - Relaxation Response Resiliency Program, SMART-3RP. This training is structured around the following four goals:~1. Education about stress response~2. Elicitation of the Relaxation Response through Mindfulness Training~3. Creating adaptive perspectives~4. Coping strategiest.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist
Description: The waitlist consists of a waiting time of 12 weeks during which participants will nog receive any type of intervention.
Study: NCT04454970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urethrotech Urethral catheterisation device (UCD)
Description: Urethral indwelling catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bardia Aquafil long term catheter
Description: Urethral indwelling catheter
Study: NCT06066307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory training
Description: Olfactory training will be performed by sniffing four specific essential oils twice daily for 30 seconds each. Participants are encouraged to visualize the item they are smelling, while they perform the procedure, in a quiet room, with their eyes closed. The odors will comprise four major odor categories: flowery (phenyl ethyl alcohol/rose), aromatic (eucalyptol), fruity (citronellal/lemon), and resinous (eugenol).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory training
Description: Olfactory training will be performed by sniffing four specific essential oils twice daily for 30 seconds each. Participants are encouraged to visualize the item they are smelling, while they perform the procedure, in a quiet room, with their eyes closed. The odors will comprise four major odor categories: flowery (phenyl ethyl alcohol/rose), aromatic (eucalyptol), fruity (citronellal/lemon), and resinous (eugenol).
Study: NCT05457946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBVD (Hexavalent vaccine)
Description: Injection within the muscle into the front area of the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBVD (Hexavalent vaccine)
Description: Injection within the muscle into the front area of the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBVD (Hexavalent vaccine)
Description: Injection within the muscle into the front area of the thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains)
Description: Injection within the muscle into the front area of the thigh
Study: NCT06314984

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group I A (Conventional needle syringe)
Description: The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the mandible by the conventional needle syringe \[Inferior Alveolar Nerve Block\].

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group I B (Conventional needle syringe)
Description: The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the maxilla by the conventional needle syringe \[Infiltration\].

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group II A (Comfort-in Jet Injector)
Description: The injection site was isolated using a cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the mandible by the needleless Comfort-in jet injector \[Inferior Alveolar Nerve Block\].

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group II B (Comfort-in Jet Injector)
Description: The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the maxilla by the needleless Comfort-in jet injector \[Infiltration\].
Study: NCT04698057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The aim of the study is to validate the desescalation of the treatment to stop ciprofloxacin prescription that may not impact the outcome of the patients but add toxicity and antibiotics selection. Placebo will be administred in the experimental arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: Will be administred to all patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Clavulanate
Description: Will be administred to all patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Will be administred to patients in the standard of care arm
Study: NCT05559294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Development of Early Childhood Education and Care Staff for Science
Description: A nine-month program consisting of three e-learning modules and three group workshops

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and care as Usual (ECAU)
Description: Active control
Study: NCT06406985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight-loss through dietary and lifestyle changes
Description: Weight-loss participants will complete one online, self-paced education session each week for 12 weeks. Education sessions focus on topics such as self-monitoring weight, meal routines, and dietary habits with an emphasis on protein and fiber intake. During these 12 weeks, participants will receive weekly messages from nutrition coaches as well as a monthly nutrition coaching call. After the first 12 weeks, participants will enter a follow-up period where nutrition coaching messaging will occur as needed and with the opportunity to still participate in a monthly nutrition coaching call. Participants are asked to weigh daily on a provided WiFi scale that automatically uploads their weight data to a website for researchers and coaches to monitor. Participants will also submit food records and self-reported weight and hip circumferences.
Study: NCT04764396

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)
Description: The fine needle biopsy (FNB) needle will be flushed with 1 mL of heparin (100 USP/mL) and then flushed with air. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed with 1 mL of heparin (100 USP/mL) and flushed with air before next pass is made.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: FNB will be performed as current standard methods in the medical procedure unit without the use of heparin priming. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed saline and or air as per current standards of care.
Study: NCT05008679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: at a dose of 75 mg twice daily
Study: NCT06433180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of fecal microbiota transplantation ( FMT capsules)
Description: Oral, capsulized, frozen fecal microbiota transplantation FMT delivering approximatively 24 g of stools taken in one day in two separate meals. Administration of the FMT after colon cleaning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of the sham (PLACEBO)
Description: Oral, capsulized, frozen capsules without fecal matter but containing cryopreservation solution will be administered at the same volume and same time point as in the experimental group. Taken in one day in two separate meals. Administration of the sham after colon cleaning.
Study: NCT04717804

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIP CT
Description: An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FB (Free-Breathing) CT
Description: A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
Study: NCT05614297

Intervention type: DIAGNOSTIC_TEST
Intervention: Knee joint laxity test
Description: Patients seen in an outpatient clinic in connection with an ACL injury or in connection with short or long-term follow-up after ACL surgery, will undergo a clinical assessment of their knee injury as part of standard care. This includes an assessment of knee joint laxity using both the Rolimeter and the Lachmeter, to allow for an assessment of agreement between the two methods.
Study: NCT06233318

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine
Description: The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pecto-intercostal Fascial Block with normal saline
Description: The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
Study: NCT05067491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented reality exposure therapy
Description: Virtual objects will be placed in the patient's visual field, superimposed on their real environment for exposure therapy.
Study: NCT05400525

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: YMETA
Description: 1 sachet containg a total of 3g i.e. 2.5g Galacto-oligosaccharides, 0.5g Bifidobacterium polysaccharides (daily)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: 3g Maltodextrin (i.e. DE 10) daily
Study: NCT06528028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ/AVI
Description: continuous infusion is used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ/AVI
Description: 2h-infusion is used
Study: NCT05028660

Intervention type: DIAGNOSTIC_TEST
Intervention: GAG score
Description: blood and urine samples to determine GAG scores
Study: NCT05709743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Within-Subjects Attentional Information
Description: Behavioral: Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
Study: NCT06296719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chit-Chat
Description: Participants will receive the 2 sessions of the Chit-Chat intervention on a weekly basis.
Study: NCT04897893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid monoglycerid (MAG-EPA)
Description: MAG-EPA is an omega-3 fatty acid classified in canada as a Natural Health Product (NHP). The NHP is approuved under the Natural Health Product number (NPN # 80050187).
Study: NCT06424678

Intervention type: OTHER
Intervention: Only data collection in the Utstein template
Description: The intervention that we will carry out in both groups will consist of collecting data from the patient (age, sex and race), on cardiopulmonary arrest, cardiopulmonary resuscitation, and the results of cardiopulmonary resuscitation.

Intervention type: OTHER
Intervention: Only data collection in the Utstein template
Description: The intervention that we will carry out in both groups will consist of collecting data from the patient (age, sex and race), on cardiopulmonary arrest, cardiopulmonary resuscitation, and the results of cardiopulmonary resuscitation.
Study: NCT05153291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bachmann's bundle lead placement
Description: Atrial lead placement at Bachmann's bundle area

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right atrial appendage lead placement
Description: Atrial lead placement in the right atrial appendage
Study: NCT05915884

Intervention type: OTHER
Intervention: SGLT-2 inhibitors
Description: This study is an observational study. It is not planned to do an interventional activity.
Study: NCT00724074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-Q PainBuster with Bupivacaine
Description: On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study: NCT05347030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: During the 12-week treatment, acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: During the 12-week treatment, Sham Acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.